AGM Statement

 
TIDMRGT 
 
AGM STATEMENT 
 
28 June 2010 
 
Commercial  Developments 
 
At todays AGM the Chairman of ReGen Therapeutics Plc ('ReGen' or the 'Company') 
<AIM:RGT> commented that since the Chairman's Statement of 3 June 2010 there are 
additional points which we would like to draw to the attention of shareholders. 
 
 
There have been encouraging developments in revenue generation.  Estimated 
revenues for the first half of 2010 are  GBP132,000 compared with total revenues in 
2009 of  GBP56,055.  This revenue has come from several of the markets where 
Colostrinin(TM) is now on sale and we look to continue this upward trend. 
 
Our Turkish licensee Eczacibasi Ilac Pazarlama A.S ('Eczacibasi')[1] has now 
confirmed that it has launched ReGen's nutritional supplement ColostrininTM 
under the local tradename 'DynaTM' in the Republic of Turkey. 
 
Since obtaining final product approval on 4 May 2010 Eczacibasi have built a new 
marketing and sales team to launch the product and have introduced the product 
to key opinion leaders in the market prior to formal launch. 
 
By way of reminder Eczacibasi are supplied with bulk blistered tablets for 
which ReGen receive a fee for the active ingredient component. These are 
then packaged locally. Revenues to ReGen from Eczacibasi pursuant to the 
minimum annual purchase commitments in the distribution agreement are estimated 
to be $52,000 in the first year and $104,000 in the second year. 
 
We would also comment that the other aspects of the business are developing as 
described in the Chairman's Statement of 3 June.  In particular a combination of 
fundraising and sales with continuing attention to costs has improved the 
Company's financial position since the year end. 
 
Science Update 
 
 
Zolpidem 
 
South African SPECT Scanning Study - Full Publication 
The full paper reporting the results of the SPECT scanning study in South Africa 
(first announced in a ReGen press release of 9 November 2009) was published in 
the journal Arzneimittel Forschung/ Drug Research. An abstract is available 
athttp://www.ncbi.nlm.nih.gov/sites/pubmed by searching under the authors names: 
Nyakale NE, Clauss RP, Nel HW, Sathekge MM. 
 
Zolpidem Website 
A website drawing together all of the currently available scientific information 
on the use of zolpidem in brain trauma has been put together and will be 
maintained by Dr Ralf Clauss (http://sites.google.com/site/zolpidemtherapy/). 
There is now a link to this from the ReGen website. 
 
Mode of Action Hypothesis Paper 
 
A paper proposing how zolpidem works to overcome the natural brain response to 
trauma has been published by Dr Clauss. 
 http://www.ncbi.nim.nih.gov/pubmed/20347531 
 
Colostrinin(TM) 
 
Austen/Stewart publications - J Nutr and Aging 
 
A publication, by Prof Brian Austen (a former scientific collaborator of ReGen) 
and a subsequent letter from Dr M. Stewart (a former collaborator and consultant 
to ReGen) further elaborate on the mechanism of how Colostrinin(TM) can protect 
human neurones in-vitro from cell death (apoptosis) induced by aggregated beta 
amyloid and suggest that this mechanism might be the basis of Colostrinin's(TM) 
protective effect in Alzheimer's disease. 
 
Abstracts of both articles are available at: 
http://www.ncbi.nlm.nih.gov/sites/pubmed by searching under the authors names. 
Douraghi-Zadeh D, Matharu B, Razvi A, Austen B. and Stewart M.G respectively. 
 
 
For further information, please contact: 
 
Percy Lomax 
ReGen Therapeutics Plc 
Tel: [phone] 
 
Roland Cornish/Felicity Geidt 
Beaumont Cornish Limited 
Tel: [phone] 
 
David Scott/Nick Bealer 
Alexander David Securities Limited 
Tel: [phone] 
 
 
 
[1] Eczacibasi http://www.eczacibasi.com is a leading Turkish industrials group 
with 40 companies, approximately 9,300 employees and revenues of $3.2bn in 
2007. Eczacibasi's Ilac Pazarlama A.S. division is based in Levent-Istanbul, 
Turkey. 
 
 
[HUG#1427734] 
 
 
 
 
 
 
 
 
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. 
The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein. 
All reproduction for further distribution is prohibited. 
 
Source: ReGen Therapeutics Plc via Thomson Reuters ONE